THREE-YEAR OUTCOMES IN A RANDOMIZED SINGLE-BLIND CONTROLLED TRIAL OF INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA

Autor: Joan Carles Domingo, María D. López-Bernal, Francisco Javier López-Román, José L. Guindo, María Argente, Jerónimo Lajara, Lafuente Mj, Lourdes Ortín
Rok vydání: 2019
Předmět:
Male
Vascular Endothelial Growth Factor A
Time Factors
Visual acuity
genetic structures
Visual Acuity
Administration
Oral
Angiogenesis Inhibitors
nutraceutics
Antioxidants
law.invention
0302 clinical medicine
Randomized controlled trial
Pro re nata
law
Original Study
Single-Blind Method
030212 general & internal medicine
omega-3 polyunsaturated fatty acids
Aged
80 and over
General Medicine
docosahexaenoic acid
Middle Aged
Dose–response relationship
Docosahexaenoic acid
Intravitreal Injections
Drug Therapy
Combination
Female
medicine.symptom
diabetic macular edema
Tomography
Optical Coherence
medicine.drug
medicine.medical_specialty
Docosahexaenoic Acids
essential fatty acids
Macular Edema
03 medical and health sciences
Pharmacotherapy
Ranibizumab
Ophthalmology
medicine
Humans
Aged
intravitreal ranibizumab
Diabetic Retinopathy
Dose-Response Relationship
Drug
business.industry
eye diseases
Regimen
030221 ophthalmology & optometry
sense organs
business
Follow-Up Studies
Zdroj: Retina (Philadelphia, Pa.)
ISSN: 0275-004X
DOI: 10.1097/iae.0000000000002114
Popis: The decrease in macular thickness observed at 24 months was maintained at Month 36 in patients with diabetic macular edema treated with a combination of intravitreal ranibizumab and oral supplementation with high-dose docosahexaenoic acid and antioxidants.
Purpose: To report 3-year results of a randomized single-blind controlled trial of intravitreal ranibizumab combined with oral docosahexaenoic acid (DHA) supplementation versus ranibizumab alone in patients with diabetic macular edema. Methods: There were 26 patients (31 eyes) in the DHA group and 29 (38 eyes) in the control group. Ranibizumab (0.5 mg) was administered monthly for the first 4 months followed by a pro re nata (PRN) regimen. In the experimental group, patients received oral DHA supplementation (1,050 mg/day) (Brudyretina 1.5 g). Results: At 36 months, mean decrease of central subfield macular thickness was higher in the DHA-supplementation group than in controls (275 ± 50 μm vs. 310 ± 97 μm) with significant differences at Months 25, 30, 33, and 34. Between-group differences in best-corrected visual acuity were not found, but the percentages of ETRDS gains >5 and >10 letters were higher in the DHA-supplementation group. Differences serum HbA1c, plasma total antioxidant capacity values, erythrocyte DHA content, and serum IL-6 levels were all significant in favor of the DHA-supplementation group. Conclusion: The addition of a high-rich DHA dietary supplement to intravitreal ranibizumab was effective to achieve better sustained improvement of central subfield macular thickness outcomes after 3 years of follow-up as compared with intravitreal ranibizumab alone.
Databáze: OpenAIRE
Externí odkaz: